Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 5482 results found since Jan 2013.
Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
Humoral and T-cell response to SARS-CoV-2 vaccination in patients with rheumatoid arthritis
CONCLUSION: In this RA cohort vaccinated with homologous and heterologous regimens against COVID-19, two out of ten patients did not develop IgG anti-SARS-CoV-2, 70% presented neutralizing activity and 65% specific T-cell response. The use of BBIBP-CorV was associated with deficient humoral and cellular response, while treatment with ABA and RTX resulted in an impaired IgG anti-SARS-CoV-2 formation and neutralizing activity. This article is protected by copyright. All rights reserved.PMID:37605835 | DOI:10.1002/acr.25221
Source: Cell Research - August 22, 2023 Category: Cytology Authors: Carolina A Isnardi Margarita Landi Leonel Cruces Pablo Maid Claudia Calle Montoro Mar ía A Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto A Ezquer Mar ía G Crespo Rocha Camila R Reyes G ómez Mar ía Á Correa Osvaldo L Cerda Marco Source Type: research
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
CONCLUSIONS: We suggest that p38 MAPK, especially p38δ, activation is associated with rituximab resistance, and deferasirox may be a candidate to overcome rituximab resistance.PMID:37599392 | DOI:10.3904/kjim.2023.134
Source: The Korean Journal of Internal Medicine - August 21, 2023 Category: Internal Medicine Authors: Min Ji Jeon Eun Sang Yu Chul Won Choi Dae Sik Kim Source Type: research
Refractory immune thrombocytopenic purpura (ITP) after accessory splenectomy: A case report and literature review
Clin Hemorheol Microcirc. 2023 Aug 18. doi: 10.3233/CH-231881. Online ahead of print.ABSTRACTImmune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a platelet count of less than 100 x 109 /L, resulting from antibody-mediated platelet destruction. Treatment for ITP typically involves steroids, and intravenous immunoglobulins (IVIG) can be added. Splenectomy is performed in cases with refractory ITP. Rituximab can suppress immunity but has limited efficacy in ITP cases. Herein, we present a rare case of a 30-year-old female who was first diagnosed with ITP and underwent a splenectomy two years later...
Source: Clinical Hemorheology and Microcirculation - August 21, 2023 Category: Hematology Authors: Asad Riaz Hossam Tharwat Ali Fawad Khan Jawad Ali Source Type: research
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
CONCLUSIONS: We suggest that p38 MAPK, especially p38δ, activation is associated with rituximab resistance, and deferasirox may be a candidate to overcome rituximab resistance.PMID:37599392 | DOI:10.3904/kjim.2023.134
Source: The Korean Journal of Internal Medicine - August 21, 2023 Category: Internal Medicine Authors: Min Ji Jeon Eun Sang Yu Chul Won Choi Dae Sik Kim Source Type: research
Refractory immune thrombocytopenic purpura (ITP) after accessory splenectomy: A case report and literature review
Clin Hemorheol Microcirc. 2023 Aug 18. doi: 10.3233/CH-231881. Online ahead of print.ABSTRACTImmune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a platelet count of less than 100 x 109 /L, resulting from antibody-mediated platelet destruction. Treatment for ITP typically involves steroids, and intravenous immunoglobulins (IVIG) can be added. Splenectomy is performed in cases with refractory ITP. Rituximab can suppress immunity but has limited efficacy in ITP cases. Herein, we present a rare case of a 30-year-old female who was first diagnosed with ITP and underwent a splenectomy two years later...
Source: Clinical Hemorheology and Microcirculation - August 21, 2023 Category: Hematology Authors: Asad Riaz Hossam Tharwat Ali Fawad Khan Jawad Ali Source Type: research
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
CONCLUSIONS: We suggest that p38 MAPK, especially p38δ, activation is associated with rituximab resistance, and deferasirox may be a candidate to overcome rituximab resistance.PMID:37599392 | DOI:10.3904/kjim.2023.134
Source: The Korean Journal of Internal Medicine - August 21, 2023 Category: Internal Medicine Authors: Min Ji Jeon Eun Sang Yu Chul Won Choi Dae Sik Kim Source Type: research
Refractory immune thrombocytopenic purpura (ITP) after accessory splenectomy: A case report and literature review
Clin Hemorheol Microcirc. 2023 Aug 18. doi: 10.3233/CH-231881. Online ahead of print.ABSTRACTImmune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a platelet count of less than 100 x 109 /L, resulting from antibody-mediated platelet destruction. Treatment for ITP typically involves steroids, and intravenous immunoglobulins (IVIG) can be added. Splenectomy is performed in cases with refractory ITP. Rituximab can suppress immunity but has limited efficacy in ITP cases. Herein, we present a rare case of a 30-year-old female who was first diagnosed with ITP and underwent a splenectomy two years later...
Source: Clinical Hemorheology and Microcirculation - August 21, 2023 Category: Hematology Authors: Asad Riaz Hossam Tharwat Ali Fawad Khan Jawad Ali Source Type: research
